IDEXX Laboratories, Inc. (IDXX)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for IDXX is $755.97, 34.9% above the last close of $560.36 on Oct 16, 2026; targets range from $615.95 to $829.06. Rating consensus: Buy.
Snapshot
- P/E39.7x
- P/E vs sector+41.0%
- P/E vs own-12.4%
- Target upside+34.9%
- ConsensusBuy
- Market cap$44.15B
- FCF yield+2.8%
- Insiders-$1.17M
- Earnings in17d
- News0.00
Why it moved
IDEXX Laboratories, Inc. (IDXX) rose 2.4% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.8%. Most of the move is specific to IDXX.
0 stories on the day (30-day average 0.4).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $560.36 · -12.1% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▼
- Above MAs3 of 4 above
- MA20×50↑ in ~6d
- RSI66
- Support0.0%
- Resistance+4.4%
- Off 52w high-26.9%
- Off ATH-26.9%
- 52w range$560.36
- Bollingerabove upper
- MACD5.08
- ATR+2.4%
- Volume1.4x
Analyst price targets
9 firms with a target in the last 12 months · last close $560.36 · as of Oct 16, 2026
Strong buy 4 · Buy 4 · Hold 5 · Sell 0 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +9.7% year over year, free cash flow 26.5% of revenue, operating margin 35.0%.
| Q2 FY2026 | Jun 30, 2026 | $1.22B | 4.19 | $323M | 64.0% | 35.0% | 27.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.14B | 3.45 | $234M | 63.4% | 31.8% | 24.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.09B | 3.08 | $323M | 60.3% | 28.9% | 22.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.11B | 3.40 | $371M | 61.8% | 32.1% | 24.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.11B | 3.63 | $152M | 62.6% | 33.6% | 26.5% |
| Q1 FY2025 | Mar 31, 2025 | $998M | 2.96 | $208M | 62.4% | 31.7% | 24.3% |
| Q4 FY2024 | Dec 31, 2024 | $954M | 2.62 | $223M | 59.8% | 27.4% | 22.7% |
| Q3 FY2024 | Sep 30, 2024 | $976M | 2.80 | $192M | 61.1% | 31.2% | 23.9% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $172.97 | -1.5% | -1.5% | +0.5% | 34.0 | $48.77B | |
| 2 | | $560.36 | +2.4% | -26.9% | +34.9% | 39.7 | $44.15B | |
| 3 |  | $266.90 | -1.5% | -3.0% | +3.6% | 33.1 | $43.93B | |
| 4 |  | $436.95 | -1.6% | -1.6% | +4.4% | 109.0 | $42.9B | |
| 5 |  | $262.54 | -2.0% | -10.6% | -16.6% | 49.0 | $39.64B | |
| 6 |  | $1,622.29 | -1.0% | -1.0% | -7.3% | 36.5 | $32.51B | |
| 7 |  | $235.00 | -1.7% | -4.7% | -0.5% | 24.9 | $25.94B | |
| 8 |  | $317.95 | -2.2% | -6.1% | +5.8% | 26.3 | $25.79B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.